(Q39301436)

English

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

0 references

author name string

V Chell

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

K Balmanno

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

A S Little

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

M Wilson

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

S Andrews

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

L Blockley

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

M Hampson

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

P R Gavine

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

S J Cook

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

0 references

publication date

6 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

3059-3070

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

describes a project that uses

0 references

Cellular signaling by fibroblast growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Fibroblast growth factors in cancer: therapeutic possibilities

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

De-regulated FGF receptors as therapeutic targets in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Oncogene addiction

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

A structure-guided approach to creating covalent FGFR inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

RUNX1T1 is overexpressed in imatinib mesylate-resistant cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Jalview Version 2--a multiple sequence alignment editor and analysis workbench

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Features and development of Coot

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

21 January 2018

Signal transduction by fibroblast growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

31 March 2020

Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

31 March 2020

Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

31 March 2020

DNA amplification in human gastric carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.319

31 March 2020

Identifiers

10.1038/ONC.2012.319

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39301436&oldid=2202761296"